STEPHEN HENNIGAN: Open Payments
NPI 1386728996 · FAYETTEVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$709 in 33 payments from 9 companies in 2025. Trend: 2023 $1,351 · 2024 $986 · 2025 $709
Food & beverage: $709
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 10 | $229 |
| ABBVIE INC. | 8 | $168 |
| Merck Sharp & Dohme LLC | 4 | $73 |
| Gilead Sciences, Inc. | 2 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $46 |
| Cumberland Pharmaceuticals, Inc. | 2 | $41 |
| Shionogi Inc | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
Products named: DOVATO, DALVANCE, AVYCAZ, CABENUVA, ZERBAXA, VIBATIV, Fetroja, NUZYRA.
Industry payments across AR — which companies pay providers there.
